Novartis' Exjade gains E.U. approval for treatment of blood transfusional iron overload

By Elaine Rigoli

Tampa, Fla., Aug. 30 - Novartis AG has received approval from the European Commission for Exjade (deferasirox), an oral iron chelator designed to provide continuous chelation coverage to remove excess total body iron with a single daily dose.

Iron chelation is needed to help patients with thalassemia, sickle cell disease, myelodysplastic syndromes and other anemias who regularly receive transfusions. Exjade provides a convenient alternative to standard therapy for adults and children through a once-daily drink, the company said.

Novartis is a pharmaceutical company based in Basel, Switzerland.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.